- Home
- NCPL vs PSTV Comparison
NCPL vs PSTV Comparison
Compare NCPL & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- PSTV
- Stock Information
- Founded
- NCPL 1984
- PSTV 1996
- Country
- NCPL United States
- PSTV United States
- Employees
- NCPL N/A
- PSTV N/A
- Industry
- NCPL Investment Managers
- PSTV Medical/Dental Instruments
- Sector
- NCPL Finance
- PSTV Health Care
- Exchange
- NCPL Nasdaq
- PSTV Nasdaq
- Market Cap
- NCPL 16.1M
- PSTV 17.0M
- IPO Year
- NCPL N/A
- PSTV N/A
- Fundamental
- Price
- NCPL $2.49
- PSTV $0.70
- Analyst Decision
- NCPL
- PSTV Strong Buy
- Analyst Count
- NCPL 0
- PSTV 3
- Target Price
- NCPL N/A
- PSTV $10.83
- AVG Volume (30 Days)
- NCPL 366.8K
- PSTV 19.1M
- Earning Date
- NCPL 09-15-2025
- PSTV 08-22-2025
- Dividend Yield
- NCPL N/A
- PSTV N/A
- EPS Growth
- NCPL N/A
- PSTV N/A
- EPS
- NCPL N/A
- PSTV N/A
- Revenue
- NCPL $812,612.00
- PSTV $5,206,000.00
- Revenue This Year
- NCPL N/A
- PSTV $8.26
- Revenue Next Year
- NCPL $101.16
- PSTV $8.39
- P/E Ratio
- NCPL N/A
- PSTV N/A
- Revenue Growth
- NCPL N/A
- PSTV N/A
- 52 Week Low
- NCPL $1.41
- PSTV $0.16
- 52 Week High
- NCPL $8.75
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- NCPL 36.18
- PSTV 60.91
- Support Level
- NCPL $2.81
- PSTV $0.45
- Resistance Level
- NCPL $3.45
- PSTV $0.90
- Average True Range (ATR)
- NCPL 0.33
- PSTV 0.12
- MACD
- NCPL -0.07
- PSTV 0.02
- Stochastic Oscillator
- NCPL 16.79
- PSTV 57.45
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).